Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright

Upstream Bio, Inc. (NASDAQ:UPB) – HC Wainwright reduced their Q3 2026 EPS estimates for Upstream Bio in a research report issued to clients and investors on Wednesday, August 12th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($0.79) per share for the quarter, down from their previous estimate of ($0.73). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($2.87) per share. HC Wainwright also issued estimates for Upstream Bio’s Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.09) EPS, FY2027 earnings at ($3.31) EPS, FY2028 earnings at ($3.13) EPS, FY2029 earnings at ($3.56) EPS and FY2030 earnings at ($3.84) EPS.

A number of other analysts have also recently weighed in on the stock. JPMorgan Chase & Co. cut shares of Upstream Bio from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $35.00 to $8.00 in a research report on Friday, June 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Upstream Bio in a research report on Monday, August 3rd. Mizuho dropped their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Finally, Truist Financial reduced their price objective on shares of Upstream Bio to $25.00 and set a “buy” rating on the stock in a research note on Tuesday. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $29.50.

Upstream Bio Stock Performance

Shares of UPB opened at $6.91 on Friday. The stock has a fifty day moving average of $6.80 and a two-hundred day moving average of $9.92. Upstream Bio has a fifty-two week low of $5.85 and a fifty-two week high of $33.68. The company has a market capitalization of $378.46 million, a PE ratio of -2.38 and a beta of 1.26.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.01. Upstream Bio had a negative return on equity of 45.92% and a negative net margin of 4,955.67%.The firm had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.56 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of UPB. GF Fund Management CO. LTD. acquired a new stake in Upstream Bio during the fourth quarter worth about $29,000. Torren Management LLC acquired a new position in Upstream Bio in the fourth quarter valued at approximately $30,000. Persistent Asset Partners Ltd bought a new position in shares of Upstream Bio during the second quarter valued at approximately $34,000. BNP Paribas Financial Markets grew its holdings in shares of Upstream Bio by 229.8% during the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after purchasing an additional 2,158 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after purchasing an additional 1,440 shares during the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.